SCHEMBL15848435

SCHEMBL15848435

CC(C)(C)OC(=O)N1CCC[C@]1(CC(=O)c1ccncc1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
NAMPT P43490 5/20 0.36
JAK3 P52333 2/20 0.36
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
USP2 O75604 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17270481 1.00 GPR119 (0.36) GPR119GRIN2BGRIN2CNAMPTJAK3
SCHEMBL5568988 0.90 KDM4E (0.41) GPR119GRIN2BGRIN2CTSHRMEN1
SCHEMBL17270495 0.90 KDM4E (0.41) GPR119GRIN2BGRIN2CTSHRMEN1
SCHEMBL17270494 0.90 KDM4E (0.41) GPR119GRIN2BGRIN2CTSHRMEN1
SCHEMBL17270449 0.88 KMT2A (0.39) GPR119GRIN2BGRIN2CNAMPTJAK3
SCHEMBL15848401 0.88 KMT2A (0.39) GPR119GRIN2BGRIN2CNAMPTJAK3
SCHEMBL18815567 0.87 MAPT (0.42) GPR119GRIN2BGRIN2CTSHRMEN1
SCHEMBL18815568 0.87 MAPT (0.42) GPR119GRIN2BGRIN2CTSHRMEN1
SCHEMBL15848546 0.87 MEN1 (0.40) GRIN2BGRIN2CMEN1KMT2A
SCHEMBL15848631 0.87 MEN1 (0.40) GRIN2BGRIN2CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637516-B2 Betulinic acid proline derivatives as HIV inhibitors HETERO RESEARCH FOUNDATION (IN) 2017-05-02 US disclosed
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2015-11-26 US disclosed
WO-2014105926-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PELP1 GPR119 3084/4885GRIN2B 3900/4885GRIN2C 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.